Hanmi Pharm has made a license contract of immunization disease treatments with Lilly

Published: 2015-03-20 12:54:51

Updated: 2015-03-20 12:54:51

Hanmi Pharm and Eli Lilly announced on the 19^th that they have made a license and cooperation contract to develop and commercialize the Hanmi Pharm’s BTK inhibitor, HM71224, related to immunization disease.

The contract has left an approval procedure for the Hart-Scott-Rodino Antitrust Improvement Acts necessary to adopt technologies that exceed certain scales.

Hanmi Pharm and Lilly, preparin...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.